Albemarle Corp. stock underperforms Friday when compared to competitors
Iowa's O hopes to stay hot vs. defense-minded Northwestern
Revealed: The bill to empty the Powerhouse Museum
Every investor has heard the phrase "buy low, sell high." It's a simple enough piece of advice that's less simple to apply. What exactly qualifies as "low"? One possible answer is when a company's shares fall significantly in one day following a setback that barely affects its long-term prospects. That's what recently happened to Vertex Pharmaceuticals ( VRTX -0.46% ) , a biotech company. Here is why now is as good a time as any to "buy low" when it comes to this stock. Vertex's pain medicine underwhelms Vertex Pharmaceuticals' suzetrigine is an investigational pain treatment. Its first approved indication could come as early as next month in treating acute pain. It will seek label expansions thereafter, including in targeting painful lumbosacral radiculopathy (LSR, a condition that results from a pinched or inflamed nerve in the lower back). Vertex Pharmaceuticals recently released data from a phase 2 study for suzetrigine in LSR. Unfortunately, the market was not impressed. The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain Rating Scale after 12 weeks of treatment. Suzetrigine led to a statistically significant reduction in pain, but so did a placebo, and the difference between the two was not particularly large. This data created some uncertainty concerning suzetrigine's efficacy in people with LSR, a condition that affects millions of patients every year, and could, therefore, be a large and lucrative market for Vertex Pharmaceuticals. That's why the company's shares dipped by more than 10% in one day after it released this data. Focus on the long game Vertex will likely still run a phase 3 study for suzetrigine in LSR that could break its way. But what if it doesn't? The biotech has many more tricks up its sleeves. It recently earned approval for its next-gen cystic fibrosis (CF) therapy, Alyftrek. Vertex has a monopoly in the CF drug market. Alyftrek is yet another improvement from its latest gem, Trikafta. Among other things, Alyftrek is just as effective despite its once-daily dosage (Trikafta is taken twice a day). The company's CF franchise continues to drive strong top-line growth. Third-quarter revenue increased by 12% year over year to $2.77 billion. There is still a good chance suzetrigine will earn approval in acute pain next month. Vertex has also been ramping up its gene-editing treatment, Casgevy, which targets two rare blood diseases. Although it has been approved for over a year in some markets, including the U.K., Casgevy will take time to impact Vertex's financial results significantly. That is the nature of gene-editing treatments. However, the medicine has a massive, multibillion-dollar opportunity. You can also look at Vertex's pipeline. It has phase 3 programs in APOL-1 mediated kidney disease and Iga nephropathy (also a kidney disease). It has earlier-stage programs in type 1 diabetes, a particularly promising project for Vertex Pharmaceuticals. The company's VX-880 could be a functional cure for patients with this chronic condition and allow them to make their own insulin, something that is typically impossible for people with type 1 diabetes. In an ongoing phase 1/2 study, 12 patients treated with VX-880 11 showed reduced or complete elimination of the need for synthetic insulin. Three of them with more than a year of follow-up also showed elimination of severe hypoglycemic events. There is still a long way to go before Vertex earns approval for VX-880, but the company has consistently demonstrated its innovative qualities. Though the phase 2 data for suzetrigine in LSR is a bit of a setback, it does little to change Vertex's long-term prospects. What happened last time the company's shares fell off a cliff following a clinical setback? That was on Oct. 14, 2020, when it announced it was giving up on a phase 2 trial for VX-814, an investigational therapy for Alpha-1 antitrypsin deficiency. And since Oct. 15, 2020, Vertex's shares have outperformed the S&P 500 , even taking into account its recent massive drop. VRTX Total Return Level data by YCharts I expect the same thing to happen this time around. Patient investors will benefit from scooping up shares of this biotech stock on the dip.NoneShe once admitted her own Insta weakness. Now she’s banning social media for kidsSAN DIEGO , Dec. 7, 2024 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in DMC Global Inc. ( NASDAQ : BOOM) shares Investors who purchased more than $100,000 in shares of DMC Global Inc. BOOM between May and November 2024 have certain options and there are short and strict deadlines running. Deadline: February 04, 2025 . Those DMC Global Inc. (NASDAQ: BOOM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On October 21, 2024 , DMC Global Inc. disclosed that it was "revising its guidance" for the quarter ended September 30, 2024 , stating that the Company's adjusted EBITDA is now expected to be approximately $5 million , down from prior guidance for $15 -18 million, and that the third quarter financial results "will include inventory and bad debt charges at DynaEnergetics totaling approximately $5 million , as well as lower fixed overhead absorption on reduced sales at both Arcadia and DynaEnergetics." The Company also revealed that the financial results will include an approximate $142 million non-cash goodwill impairment charge "associated with DMC's December 2021 acquisition of a controlling interest in Arcadia ." On November 4, 2024 , DMC Global Inc released its third-quarter financial results for the period ending September 30, 2024 . Among other results, the Company reported third quarter sales of $152.4 million , down 11% sequentially and year-over-year, as well as the previously disclosed non-cash goodwill impairment charge. Shares of DMC Global Inc. BOOM declined from $15.98 per share on May 3, 2024 , to as low as $7.16 per share on November 21 , 2024. On December 06, 2024 , an investor in NASDAQ: BOOM shares filed a lawsuit against DMC Global Inc. The plaintiff alleges that between May 3, 2024 and November 4, 2024 , the defendants made materially false and misleading statements and failed to disclose the following adverse facts about DMC Global's business, operations, and prospects which were known to defendants or recklessly disregarded by them: (i) the goodwill associated with the company's principal business segment, Acadia Products, was overstated due to the adverse events and circumstances affecting that reporting segment; (ii) DMC Global's materially inadequate internal systems and processes were adversely affecting its operations; (iii) the company's inadequate systems and processes prevented it from ensuring reasonably accurate guidance and that its public disclosures were timely, accurate, and complete; (iv) as a result, defendants misrepresented DMC Global's operations and financial results; and/or (v) as a result, the company's public statements were materially false, misleading, or lacked a reasonable basis when made. Those who purchased shares of DMC Global Inc. BOOM should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 mail@shareholdersfoundation.com 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon. View original content to download multimedia: https://www.prnewswire.com/news-releases/lawsuit-for-investors-who-lost-over-100-000-in-shares-of-dmc-global-inc-nasdaq-boom-between-may-and-nov-2024-announced-by-shareholders-foundation-302325435.html SOURCE Shareholders Foundation, Inc. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
At the not-that-old age of 39, I've already seen the world around me change a lot. So, I'm fascinated by how even older adults have seen trends come and go. Recently, older adults on Reddit shared wonderful things from the past that younger generations don't even know they're missing, and it made me really nostalgic (yes, even for the things I was too young to experience). Here's what they had to say: 2. "Handwritten letters." — r_colo "Particularly thank-you letters." — DifficultStruggle420 3. "Heading down to the video store on a Friday night and crossing your fingers that there are still copies of the new releases. Getting a massive bag of chips, popcorn, and a soft drink, getting home, and having the best night of the week." — YouGottaRollReddit 5. "The concept of feeling totally safe as a kid in school, except for the schoolyard bully and the duck and cover drills." — vmdinco 6. "Small towns filled with individually owned businesses that created a community, instead of chains of corporate-owned replicas of the store one town over." — Gilligan_G131131 "I moved to a tiny town and it is about a 45 drive to any chain, except Dairy Queen — the only fast-food joint in town. It is like living in the Gilmore Girls , and I love it. Plus, my husband bought a fixer-upper for $6k about six years ago and has fixed it up cash only. I work from home and now have about $1.5k in monthly expenses (car, insurance, groceries, etc.) and have a plan to save $700k in the next 10 years. The American Dream is still alive, at least in rural Minnesota, but most people can’t live without endless consumption." — Opandemonium 8. "Secret songs at the end of a CD." — MartyFreeze "Oh yeah! My friends and I would always call those 'Track 99.' That reminds me — how about the beep tones at the end of a cassette tape to let you know you had to eject it and flip it over?" — drummerboy-98012 9. "Bench front seats in cars. There was nothing better in high school than having your girlfriend with you in a car that had a bench front seat." — ResponsibleFreedom98 11. "Being able to just disappear for a couple of weeks on vacation. No phones. Nothing. Just loose on the continent on a motorcycle or in a car. No 'checking in.' No work intrusions. Just complete unaccountability until we decided to resurface." — kbasa 12. "Seeing the Milky Way at night." — newleaf9110 14. "Stupid and small, but I used to love calling time and weather. 'At the tone, the time will be...' We had a rotary phone that would actually call after the first three numbers, so you didn't have to dial the final random four." — mereseydotes "Wow, I’d totally forgotten about that. Thanks for bringing a smile to my face!" — DC2LA_NYC 15. "Phone booths. If we had to call home and we didn’t have a dime on us, we could dial the operator (0) and tell them we needed to use our 10 cent credit and they would put the call through with no questions asked." — Jet-pilot 17. "Calling a business and having a nice, helpful person answer the phone within four rings and then help you." — ColoradoInNJ "I am feeling this hard. Yesterday, I spent 45 minutes on the phone. A total of three minutes, I was talking to an actual human; Two of the humans couldn't help and had to transfer me to a third, who initially kept repeating the script 'til they realized what I actually needed." — Mammoth_Ad_3463 18. "Being able to go out cruising with your friends and nobody knows where you are or what you’re doing, and the only rule is to be home by curfew. I feel bad for kids whose parents watch their every single move. I can’t imagine how suffocating that must feel." — Nofrillsasmr "On my co-worker's daughter's first day of high school, she was glued to her phone, watching the app she had tracking her daughter (yes, the daughter knew about the tracker). 'Now she's walking to History.' 'Now the day is over, and she's walking home.' I can't imagine that's healthy for the daughter OR her mother." — DoctorRabidBadger 20. "Real social interaction seems to be missing these days. People should have long, thoughtful conversations sometimes. Instead they have shallow conversations and seem to prefer typing out texts rather than an actual phone call. They'll spend so much money and effort to put something on social media so someone clicks like on their page but actually miss simply enjoying the moment. I see people worrying more about taking selfies or videos at events rather than enjoying the event or, shock, talking to their companions." — Garden_Lady2 "At Thanksgiving this year, I watched the parents of a little boy sit at the table looking at their phones while he was trying to get their attention. It made me so sad. He's being raised by people who are privileging a phone screen over eye contact, connection, attentiveness, etc." — hellocutiepye 21. "A bunch of different products have been ruined in the name of profitability. I feel bad knowing kids will grow up thinking shrinkflated products are the normal size of things, like cereal boxes an inch thick and tiny candy bars. And so many of the processed foods in the US were once much better than they are now. I miss the old Twinkies and fruit pies." — loztriforce 23. "Not having to know everyone's opinions. Thanks to social media, negativity and hate are spewed towards total strangers. I can't imagine people saying some of those things face-to-face with a stranger. I feel like I liked people better when I didn't know everything about them." — Cute-as-Duck21 24. "Nothing. They don't know how to do their own nothing, make up their own games or pastimes. It's all manufactured for them on the Internet, or programmed for them by parents." — Tall_Mickey 26. "Truly shared pop culture . Like going to school/work and everyone had watched the same thing on TV on the night before (especially if it was a big "event" like a miniseries or something). More or less familiar with the same music, saw the current movies because you could only see them when they were in the theater." — bookant 27. "Do you remember when you would wait in line to buy tickets to a concert? It was first come, first serve. And ticket prices were reasonable. I loved it because the best seats went to the best fans. Now all the tickets go to brokers online that are then resold at triple the price. The only one that wins is Ticketmaster." — Superdiscodave "Standing in line for hours to buy concert tickets was a social thing. It was fun, and we didn't mind doing it. Total strangers stuck together just hanging out and having fun. I don't think there is anything like it now, and if there was, most people would just stand there scrolling and not interacting with each other." — Granny_knows_best 29. "Local radio. Back in the '70s and '80s and even into the early '90s, local bands could get radio airplay on their local stations. As a result, they'd get a local following, and people would go out to clubs to see their favorite local bands play. In places like Boston, the club scene was robust enough that pretty much anyone who picked up a guitar could get a gig somewhere. I miss going out to see my friends play at some crappy little club. Kids don't go out to see music anymore unless it's a stadium show with a mega-star like Taylor Swift . I think it's because they don't listen to the radio anymore. And even if kids listened to the radio, these days almost all radio stations that are still around are corporate owned, and there's no way for a local band would get any airplay." — hermitzen 30. "The anticipation and excitement of getting a roll of film developed." — lrswager "And severe disappointment when mum’s finger was ALWAYS in the way or all the heads were cut off." — PurpleCollarAndCuffs 32. And finally, "I grew up in mid-Missouri in the '60s. My family didn’t have air conditioning anywhere. It was hot because it was summer. It was normal. I slept against the screen widow and hoped for a breeze. As a young girl, during the long, hot afternoons, I lay in a hammock hung from a metal frame on the screen porch. The ceiling fan was always on. I read chapter books that felt so real my reality faded." "My family moved into the air-conditioned world in 1970. I continued my love of books but never completely disappeared into the pages as completely as I did on the shady porch." — pyrofemme What's something from the past that you think younger generations are missing out on? Tell us what you think in the comments.There is no evidence that Wayfair was ever involved in child traffickingTHOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE Amgen
How Do Aircraft Management Companies Work?
2 brilliant (but very different) shares I want to buy if they get cheaper in 2025!A few weeks ago, that in November, “players will be able to play and purchase Xbox games directly from the Xbox App on Android.” It’s almost December and the feature still isn’t live, but Bond says it’s not Microsoft’s fault. The problem is that Microsoft would only be able to do it once a court order takes effect that , like opening it up to competition and ending the requirement for apps to use Google Play Billing. On October 18th, Judge James Donato granted Google’s for a stay while it appeals his ruling that the Android app store is an illegal monopoly, which could leave things hanging in the balance for quite a while. Bond acknowledged that reality , writing, “Due to a temporary administrative stay recently granted by the courts, we are currently unable to launch these features as planned. Our team has the functionality built and ready to go live as soon as the court makes a final decision.” It’s a frustrating situation for anyone hoping to see more options available on their Android-powered devices that don’t require rooting or other workarounds, and Microsoft its mobile app store strategy for . /